Le Lézard
Classified in: Health
Subject: FDA

EnsiteVascular receives FDA market clearance for SiteSealtm SV vascular closing device's second indication


OLATHE, Kan., April 20, 2021 /PRNewswire-PRWeb/ -- EnsiteVascular announces today it received its second U.S. Food and Drug Administration (FDA) market clearance for the company's SiteSeal SV (small vessel) VCD to achieve hemostasis of the brachial artery after a transbrachial endovascular procedure.

The FDA's market clearance occurred once the agency reviewed EnsiteVascular's Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.

SiteSeal SV is a new closure device designed for closure of small arterial vessels, specifically brachial, radial and pedal. It simulates external compression, but removes the associated variables, leaving nothing behind. SiteSeal SV applies invariant pressure to the vessel wall of the access site by utilizing an internal stainless steel spring, which functions as a shock absorber to dampen blood pressure fluctuation.

"The gold standard for closure of the brachial artery has always been manual compression. However, there is a significantly high rate of major complications associated with manual compression, up to 14%. These include pseudo aneurysms, thrombosis and excess bleeding, with over 60% requiring surgical repair," says Rex Teeslink, M.D., medical director, EnsiteVascular.

"Currently, there is no other device with FDA market clearance for closure of brachial artery access sites. With FDA's clearance for SiteSeal SV to achieve hemostasis of the radial artery after a transradial procedure or the brachial artery after a transbrachial procedure, we are making progress toward a new and better standard of care for these endovascular procedures," says Dr. Teeslink.

About Ensite Vascular
EnsiteVascular was founded to improve vascular closure outcomes for physicians and the increasing number of patients requiring endovascular procedures, both arterial and venous. In addition, SiteSeal SV leaves nothing behind within the vessel, vessel wall or surrounding soft tissues. Visit ensitevascular.com for more information.

Media Contact

Tom Reidy, EnsiteVascular, +1 816-260-8476, [email protected]

 

SOURCE EnsiteVascular


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: